Biocon could be set to achieve long-awaited US Food and Drug Administration approvals for the company and partner Viatris’ proposed biosimilars to Avastin (bevacizumab) and NovoLog (insulin aspart) in due course, with the Indian biotech awaiting key FDA site inspections in August to get the products over regulatory line.
Both products were recently named by Viatris as anticipated new product launches for 2022 which did not currently hold FDA...






